Microbiological labelling system developer C4 Diagnostics, which is partly based on Aix-Marseille Université research, has been backed by investors including Bpifrance.

Colposcope developer Dysis has closed a series B round featuring existing investor Lundbeckfonden Ventures that will fund growth and R&D.

Initial public offerings of companies from the life sciences sector appear to be rebounding in number during the first half of 2018 and news stories on our web from the past couple weeks clearly attest to it.

Cannabis-based medicine developer Oxford Cannabinoid Technologies has secured $10m in a round led by Imperial Brands' corporate venturing unit.

Liquidia Technologies, a spinout from UNC Chapel Hill, has filed to raise up to $57.5m in its initial public offering.

Novo and returning investor Boehringer Ingelheim both contributed to the second tranche of a round that is now just over $40m in size.

PPD and Siemens-backed biopharmaeutical developer Liquidia Technologies has filed to raise up to $57.5m in its initial public offering.

The Pfizer and GE-backed medical device developer has closed its initial public offering after the underwriters took up the over-allotment option.